Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation

Inclusion Criteria: * Documented diagnosis of retinitis pigmentosa based on a genetic test confirming the presence of a monogenic mutation that affects a gene involved in the visual signalling process specifically at the level of RPEs, namely RPE65 or LRAT, or MerTK * 18 years old ≤ Age ≤ 65 years old For patient of the first cohort: * Visual acuity ≤ 20/200 in the best eye (legally blind) \- For patient of the second cohort: * 20/63 \> Visual acuity \> 20/200 in the worst eye And * Visible photoreceptor outer nuclear layer (ONL) on a spectral domain optical coherence tomography (OCT) scan For the two cohorts: * Negative serum pregnancy test in women of childbearing potential (a woman who is two years post-menopausal confirmed by a physician or surgically sterile is not considered to be of childbearing potential) * Female patients of childbearing potential (if sexually active), committed to use two methods of contraception starting from the enrollment, during Mycophenolate Mofetil (MMF) treatment and for 6 weeks after the last dose of MMF * Sexually active men (including vasectomized men) committed to use condoms during from the first day of MMF treatment and for at least 90 days after cessation of treatment * Signed informed consents by the patient or legal guardian(s). For patients unable to give consent, authorization to participate to the study will be collected close to their legally authorized representative * Affiliated to or a beneficiary of a health care syst…